Join the Conversation with Prof. Kenneth S. Kosik and Dr. Tal Sharf

Interview and Featured Publication Join the Conversation with Prof. Kenneth Kosik and Dr. Tal Sharf Recently, Dr. Tal Sharf, Prof. Kenneth S. Kosik and colleagues released a pre-print on their novel work entitled, “Human brain organoid networks”, currently under revision. Aiming to explore the physiological behavior of neuronal circuits within organoids, this work demonstrates that human brain organoids have self-organized neuronal assemblies of sufficient size, cellular orientation, and functional connectivity to co-activate and generate field potentials from their collective transmembrane…

Read More

HyVIS project

MaxWell Biosystems Becomes a Key Partner in a €3M EU-Financed Project “HyVIS”: Next Generation Prosthesis for Visual Restoration Hybrid Synapse for Vision (HyVIS) is a project funded by European Union Horizon 2020 FET-OPEN program 1, which aims to combine several technologies to achieve the groundbreaking restoration of synaptic light-mediated input in retinas with impaired photoreceptors, leading to treatments for diseases such as in retinitis pigmentosa and age-related macular degeneration (AMD). The key focus of HyVIS project is the development of an artificial light-sensitive prosthesis,…

Read More

Observing the activity of human-derived neurons in health and in disease

The combination of two technologies—induced pluripotent stem cells and high-density microelectrode arrays—offers an unprecedented platform to study human brain activity in detail outside the body.    Back in 2006, Prof. Yamanaka and colleagues revealed a technique to reprogram adult skin cells into embryonic-like cells called induced pluripotent stem cells or iPSCs. This Nobel Prize winning technology enables access to human neurons derived from adult blood or skin cells in a high-throughput manner, thus opening up the possibilities to study neurological…

Read More

MaxWell Biosystems Completes CHF 4 million Series A Financing Round

Zurich, Switzerland, 16 December 2020 – MaxWell Biosystems AG, a spin-off from ETH Zürich founded in 2016 announced today the closing of a CHF 4 million Series A financing round to further industrialize and scale-up the production of their consumables, so called multiwell high-density microelectrode array (HD-MEA) plates. Such scale-up will enable the customers of MaxWell Biosystems in the pharmaceutical industry to run functional drug screenings at a higher throughput and ultimately contribute to accelerate the development of drugs targeting…

Read More

MaxWell Biosystems introduces its new headquarters in Zurich

Since 2016, MaxWell Biosystems was located in the same premises as the Department of Biosystems Science and Engineering at ETH Zurich in Basel. With the growing team and the need for our own headquarters, we searched and found our new home in Zurich. With the dynamic startup ecosystem, world-class universities, and of course the beautiful lake and mountains, Zurich is a great place for MxW. It is here where we will continue to grow the team, develop new products, and connect to…

Read More
Contacts






Albisriederstrasse 253
8047 Zurich, Switzerland
+41 44 244 24 24
Schedule a call
info@mxwbio.com
Subscribe to our Newsletter